The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition-Reference-Cited by-同舟云学术

The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition

Published:2018-12-12 Issue: Volume: Page:
ISSN:0906-6705
Container-title:Experimental Dermatology
language:en
Short-container-title:Exp Dermatol

Author:

Guttman‐Yassky Emma¹,Hanifin Jon M.²,Boguniewicz Mark³,Wollenberg Andreas⁴,Bissonnette Robert⁵,Purohit Vivek⁶,Kilty Iain⁷,Tallman Anna M.⁸,Zielinski Michael A.⁹

Affiliation:

1. Department of DermatologyIcahn School of Medicine at Mount Sinai New York New York

2. Department of DermatologyOregon Health and Science University Portland Oregon

3. Department of PediatricsNational Jewish Health Denver Colorado

4. Department of Dermatology and AllergyLudwig Maximilian University Munich Germany

5. Innovaderm Research Inc Montreal Quebec Canada

6. Pfizer Inc Groton Connecticut

7. Pfizer Inc Cambridge Massachusetts

8. Pfizer Inc New York, New York

9. Pfizer Inc Collegeville Pennsylvania

Funder

Pfizer

Publisher

Wiley

Subject

Dermatology,Molecular Biology,Biochemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/exd.13808

Reference113 articles.

1. Public Health Burden and Epidemiology of Atopic Dermatitis

2. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three

3. Eczema Prevalence in the United States: Data from the 2003 National Survey of Children's Health

4. Guidelines of care for the management of atopic dermatitis

5. Guidelines of care for the management of atopic dermatitis

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phosphodiesterase-4-Inhibitoren in der Dermatologie;Die Dermatologie;2024-08-30

2. An Encompassing Review on Therapeutic Targets, Therapies and Nanostructure Based Formulations for Atopic Dermatitis;International Journal of Pharmaceutical Sciences and Nanotechnology(IJPSN);2024-08-15

3. Revisiting immunotherapeutic strategies for the management of atopic dermatitis;Exploration of Asthma & Allergy;2024-08-09

4. Dupilumab facial dermatitis in atopic dermatitis patients ameliorated by topical crisaborole: An open‐label case series study;Journal of the European Academy of Dermatology and Venereology;2024-08-06

5. An Interim Report of a Phase 3, Long-Term, Open-Label Study to Evaluate Efficacy and Safety of Difamilast Ointment in Japanese Infants with Atopic Dermatitis;Dermatology and Therapy;2024-07-29